Biotech Values

[iwfal]

VRUS - Genisi - thanks for the data. In particular I found it interesting that starting with one drug, and then adding the second later results in a better end-of-treatment response then just doing combo the entire time.


PS I was wrong in my overly cynical interpretation of their abstract. They did have one cohort that did have all subjects below LOD. But all the others had at least some above LOD.